FDA Confirms Nose Ointment Wasn't Pulled for Being Terrible
Published Date: 12/12/2025
Notice
Summary
The FDA has decided that BACTROBAN (mupirocin) nasal ointment, 2%, wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Makers May Seek Approval
If you make generic drugs, you can now apply to sell a generic version of BACTROBAN (mupirocin) nasal ointment, 2%. The FDA determined this product was not withdrawn for reasons of safety or effectiveness, so abbreviated new drug applications (ANDAs) referencing this listed drug may be approved if they meet all other legal and regulatory requirements.
More Affordable Options Possible
You (patients and pharmacies) could see more affordable options for BACTROBAN (mupirocin) nasal ointment, 2%, because the FDA found it was not withdrawn for safety or effectiveness and said generic versions may be approved. This change makes it possible that lower-cost generic versions could enter the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-22681 — Determination That DEMEROL (Meperidine Hydrochloride) Tablet, 100 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that DEMEROL 100 mg tablets and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can expect these meds to stay available without any surprise price hikes or shortages.
Next: 2025-22683 — Pfizer Inc., U.S. Agent for King Pharmaceuticals LLC, et al.; Withdrawal of Approval of 20 Abbreviated New Drug Applications
The FDA is officially pulling the plug on 20 drug approvals because the companies, including Pfizer and Monarch Pharmaceuticals, told the FDA they stopped selling these medicines. This change kicks in on January 12, 2026, but companies can apply again if they want. No money penalties here—just a cleanup to keep the drug list fresh and accurate.